Sponsored Podcasts

The first dose of a self-injectable therapy is a critical moment that often determines whether patients move forward with treatment or abandon it due to uncertainty. Noble’s SureStartRx™ program addresses this challenge by sending remote demonstration kits through specialty pharmacies, allowing patients to practice injections and build confidence before their first dose. Research shows that when demonstration kits are added to standard support, patients initiate therapy sooner, adhere better in the short term, and stay on treatment longer. In this discussion, Noble’s Director of Patient Engagement Services, Sean Glynn, explains how improving patient confidence at the start of therapy can protect both patient outcomes and long-term brand value.

Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.

Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.

When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.

In the pharmaceutical industry, patient engagement should be centered in health education, communication, and strategy during drug discovery and throughout the product lifecycle. Cheryl Lubbert, CEO of Reverba, discusses the importance of a patient-first mindset in the industry.

Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.

Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.

A Frost & Sullivan industry-wide survey reveals which insights most pharmaceutical companies have mastered and which are still painful or impossible to extract and details the complexity of the process, the confidence companies have in their findings, and more. Hear Web Sun, President and Co-founder of Komodo Health, share what's driving these challenges and how you can overcome them.

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.

MilliporeSigma’s Stephen Wing, head of Analytical and Logistical Services, discusses the ways in which digital transformation and data transparency dramatically enhance supply chains, and how manufacturers are using the company’s eMERGE™ platform to improve overall efficiencies.

Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS’s approach for Patient Outcomes Impact (POI).

Increasingly clinical pharma and biotech organizations are deciding to commercialize on their own; just as Contract Research Organizations (CROs) transformed clinical trial operations, Contract Commercial Services are transforming commercial operations. Emerging service models offer new options for clinical organizations. In this podcast, Brent Herspiegel, CEO, and Santosh Naik, Partner, Herspiegel Consulting, share the considerations for pharma and biotech organizations when deciding on their commercial path and partner. How Contract Commercial Services can mitigate common launch risks, what we can learn from Herspiegel Consulting’s experience with 100+ pharma product launches.

Learn about the evolving cyber-threat landscape affecting the pharmaceutical industry and the recommended approach to addressing those threats.

Today’s labs are not sufficient to handle tomorrow’s challenges. What will labs in 2030 or 2040 look like? Mikael Hagstroem, CEO at LabVantage Solutions and expert in harnessing data and analytics, discusses the three phases of digital transformation needed to reimagine business models, achieve better performance, and create long-term sustainable advantage. It starts with changing our labs – the technologies, processes, ways of working, and data solutions.

Curia is proud to partner with pharma and biotech companies to make new medicines that save lives. In order to be able to do that, Curia needs to be constantly innovating. In this podcast, you will learn from Curia’s VP of Portfolio and Sourcing, James Grabowski, about Curia’s small and large molecules most recent technologies, and capabilities.

Real world data (RWD) and artificial intelligence (AI) offer an unprecedented opportunity for Medical Affairs professionals to gather and share deeper insights about patients, including insights regarding disease progression, outcomes, and treatment response, as well as additional insights about patients’ journeys prior to diagnosis and after treatment initiation. Cindy Weber, of IQVIA’s Artificial Intelligent Solutions team explains how embracing RWD and technology, and the opportunities they provide, is helping to transform Medical Affairs and is enabling professionals to create better, more meaningful, connections with healthcare professionals; thereby helping to improve patient care.

In the past, patient-level insights were achieved through time-consuming methods requiring substantial manual effort to produce static reports. With the help of technology and machine learning, that’s no longer the case. Join Andy Burch and Brian Smith, two thought leaders with a breadth of experience in AI-ML solutions, as they dive into the benefits of bringing automated data in to dynamic visualization products and how they can help you achieve instant insights.

In this podcast, co-founder and CTO of Emulate, Inc, discusses why now is the time for researchers to accelerate their transition from animal models to human relevant-science with Organ-on-chip technology. There is no doubt that animal models have contributed to major advances in medicine, however, a growing body of evidence suggests that animal models are seriously lacking in both sensitivity and specificity when it comes to predicting drug toxicity in humans. In a recent study published to bioRxiv, researchers found the human Liver-Chip to have an 87% sensitivity and 100% specificity when differentiating hepatotoxic from non-hepatotoxic small molecules. Importantly, all 22 hepatotoxic drugs included in the study had previously been classified as safe due to a lack of toxicity in animal models. Collectively, these compounds resulted in 208 patient fatalities and 10 liver transplants. Had the human Liver-Chip been used during preclinical screening of these compounds, it’s likely that many of these fatalities could have been avoided. By adopting organ-on-a-chip, you can help make the drug development process safer, more efficient and more humane.

As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.

As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?

Local peer-to-peer learning relationships are a critical part of the overall decision to try to adopt new medical innovations, but they are very challenging to identify. In this podcast, we discuss current best practices for identification of locally influential thought leaders and mapping their learning communities.

In Episode Three of the Syneos Health Dedicated Dialogue podcast series, we uncover how the proliferation of new digital health technologies, telemedicine and mobile nursing services are helping fuel novel clinical trials. These range from community-based studies, which are administered through PCPs, local health centers and outpatient facilities in lieu of academic research centers, to hybrid and fully virtual trials designed around patients in their homes, with or without a synthetic control arm replacing patients on placebos. Additionally, we share new insights about how trial sponsors discovering new ways to engage participants, enhance data capture and devise pathways to put patients at the center of clinical trials across the biopharmaceutical product development continuum.

Peer-to-peer learning relationships, such as Thought Leader Networks, are critically important for successful adoption of medical innovations. Learn how these networks, or the different types of “communities”, each play a unique and complementary role in the adoption process.

Understand the value of involving thought leaders in engagement planning and learn why it is important to the strategy of a product’s lifecycle. IQVIA offers a customizable cloud-based platform to facilitate Thought Leader Engagement Planning & Tracking with coordinated next-generation customer engagement across all channels.

Go beyond the hype of digital transformation and learn its true promise. With advanced analytics in your pharma labs, you can transform all your data into actionable scientific and business insights that lead to better outcomes. LabVantage Solutions is working with pharmaceutical companies worldwide to integrate their labs with their enterprise digital ecosystems. Find out how LabVantage’s informatics platform, complete with AI-powered, self-service analytics, is making a difference across the pharmaceutical industry.

In Episode Two of the Syneos Health Dedicated Dialogue podcast series, we reveal how harnessing broad expertise across the product development lifecycle leads to relevant, effective and efficient solutions that speed commercial success and bring novel drugs to patients sooner to improve patient care.

In Episode One of the Syneos Health Dedicated Dialogue podcast series, we discuss how harnessing the drivers of modern customer engagement informs decisions in product development, leading to enhanced experiences for patients and healthcare providers from lab to life.

Learn how Frontage Laboratories started, recent growth and expansion, and the future vision of Frontage